Browse > Article

Effects of Amlodipine on the pharmacokinetics of Repaglinide  

Choi, Dong-Hyun (College of Pharmacy, College of Medicine, Chosun University)
Choi, Jun-Shik (College of Pharmacy, College of Medicine, Chosun University)
Publication Information
Korean Journal of Clinical Pharmacy / v.21, no.3, 2011 , pp. 215-223 More about this Journal
Keywords
Repaglinide; Pharmacokinetics; Amlodipine; CYP3A4; Rat;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Kungys G, Naujoks H, Wanner C. Pharmacokinetics of amlodipine in hypertensive patients undergoing haemodialysis. Eur J Clin Pharmacol 2003; 59: 291-295.   DOI   ScienceOn
2 Abernethy DR. Pharmacokinetics and Pharmacodynamics of amlodipine. Cardiology 1992; 80: 31-36.   DOI   ScienceOn
3 Meredith PA, Elliott HL. Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet 1992; 22: 22-31.   DOI   ScienceOn
4 Nishio S, Watanabe H, Kosuge K, et al., Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens Res 2005; 28: 223-227.   DOI   ScienceOn
5 Kim KA, Park PW, Park JY. Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects. Chirality 2009; 21: 485-491.   DOI   ScienceOn
6 Darvari R, Boroujerdi M. Concentration dependency of modulatory effect of amlodipine on P-glycoprotein efflux activity of doxorubicin - a comparison with tamoxifen. J Pharm Pharmacol 2004; 56: 985-991.   DOI   ScienceOn
7 Harmsze AM, Robijns K, van Werkum JW, et al., The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemost 2010; 103: 920-925.   DOI   ScienceOn
8 El-Houssieny BM, Wahman LF, Arafa NM. Bioavailability and biological activity of liquisolid compact formula of repaglinide and its effect on glucose tolerance in rabbits. Biosci Trends 2010; 4: 17-24.
9 Marbury TM, Ruckle JL, Hatorp V, et al., Pharmacokinetic of repaglinide in subjects with renal impairment. Clin Pharmacol Ther 2000; 67: 7-15.   DOI   ScienceOn
10 Hatorp V, Won-Chin H, Strange P. Repaglinide pharmacokinetic in healthy young adult and eldery subjects. Clin Ther 1999; 21: 702-710.   DOI   ScienceOn
11 Gromada J, Dissing S, Kofod H, et al., Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic 113 calcium levels in beta TC3 cells and rat pancreatic beta cells. Diabetologia 1995; 38: 1025-1032.   DOI   ScienceOn
12 Ruzilawati AB, Wahab MS, Imran A, et al., Method development and validation of repaglinide in human plasma by HPLC and its application in pharmacokinetic studies. J Pharm Biomed Anal 2007; 43: 1831-1835.   DOI   ScienceOn
13 Culy JR, Jarvis B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs 2001; 61: 1625-1660.   DOI   ScienceOn
14 Bidstrup TB. Björnsdottir, I., Sidelmann, U. G., et al., CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol 2003; 56: 305-314.   DOI   ScienceOn
15 Bauer E, Beschke K, Ebner T, et al., Biotransformation of [$^{14}C$] repaglinide in human, cynomolgus monkey, dog, rabbit, rat and mouse. Diabetologia 1997; 1: 326-332.
16 Chang C, Bahadduri PM, Polli JE, et al., Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos 2006; 34: 1976-1984.   DOI   ScienceOn
17 Gomes MB, Giannella-Neto D, Faria M, et al., Estimating cardiovascular risk in patients with type 2 diabetes: a national multicenter study in Brazil. Diabetol Metab Syndr 2009; 1: 22-28.   DOI
18 Kajosaari L, Niemi M, Neuvonen M, et al., Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 2005; 78: 388-399.   DOI   ScienceOn
19 Crespi CL, Miller VP, Penman BW. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 1997; 248: 188-190.   DOI   ScienceOn
20 Han CY, Cho KB, Choi HS, et al., Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells. Carcinogenesis 2008; 29: 1837-1844.   DOI   ScienceOn
21 Gonzalez FJ. Cytochrome P450 in humans. In: Schenkman JB, Grein H, editors. Cytochrome P450: handbook of experimental pharmacology. 1993; Vol. 105: Berlin: Springer- Verlag.
22 Li AP, Kaminski DL, Rasmussen A. Substrates of human hepatic cytochrome P450 3A4. Toxicology 1995; 104: 1-8.   DOI
23 Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992; 22: 1-21.   DOI   ScienceOn
24 Kelly PA, Wang H, Napoli KL, et al., Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4. Eur. J. Drug Metab Pharmacokinet 1999; 24: 321-328.   DOI   ScienceOn
25 Bogaards JJ, Bertrand M, Jackson P, et al., Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 2000; 30: 1131-1152.   DOI   ScienceOn
26 Guengerich FP, Martin MV, Beaune PH, et al., Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1986; 261: 5051-5060.
27 Lewis DFV. Cytochrome P450. Substrate specificity and metabolism. In: Cytochromes P450. Structure, Function, and Mechanism. Taylor & Francis: Bristol, 1996; 122- 123.
28 Cao X, Gibbs ST, Fang L, et al., Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res 2006; 23: 1675-1686.   DOI   ScienceOn
29 Benet LZ, Cummins CL, Wu CY. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab 2003; 4: 393-398.   DOI   ScienceOn
30 Cummins CL, Jacobsen W, Benet LZ. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002; 300: 1036-1045.   DOI   ScienceOn
31 Saeki T, Ueda K, Tanigawara Y, et al., P-glycoproteinmediated transcellular transport of MDR-reversing agents. FEBS Lett 1993; 324: 99-102.   DOI   ScienceOn
32 Wacher VJ, Salphati L, Benet LZ. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 2001; 46: 89-102.   DOI   ScienceOn
33 Kivisto KT, Bookjans G, Formm MF, et al., Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. Br. J Clin Pharmacol 1996; 42: 387-389.
34 Zhang QY, Dunbar D, Ostrowska A, et al., Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 1999; 27: 804-809.
35 Niemi M, Neuvonen PJ, Kivisto KT. The cytochrome P450 3A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 2001; 70: 58-65.   DOI   ScienceOn
36 Niemi M, Backman JT, Neuvonen M, et al., Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and Pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 2003; 46: 347-351.   DOI